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Introduction {#sec1}
============

Lymph node (LN) functional organization is formed and maintained by stromal cells ([@bib41]). Once thought to provide only the necessary scaffolds to support the architecture of the tissue, LN stromal cells are now recognized as key players in immunity ([@bib9]). Four main populations of stromal cells can be defined in LNs: podoplanin (PDPN)^−^CD31^+^ blood endothelial cells (BECs), PDPN^+^CD31^+^ lymphatic endothelial cells (LECs), PDPN^+^CD31^−^ fibroblastic reticular cells (FRCs), and PDPN^−^CD31^−^ double-negative cells (DNs) ([@bib55]). Among these, the FRC population is the most abundant subset. A recent small conditional RNA sequencing (scRNA-seq) analysis showed that FRCs may contain different subpopulations with specific locations and functions ([@bib68]). FRCs form a connected 3-dimensional (3D) network that spans the T cell area and interfollicular regions of LNs. FRCs regulate the lymphocyte homeostasis ([@bib13], [@bib41]) and induction of peripheral tolerance ([@bib17], [@bib22], [@bib39]). Furthermore, contraction through the FRC network also regulates LN size during immune responses. Interactions between FRC and C-type lectin-like receptor 2-expressing (CLEC-2^+^) migratory dendritic cells (DCs) transiently inhibit PDPN-dependent actomyosin contractility during the acute phase of the immune response ([@bib2], [@bib4]), allowing rapid LN expansion.

LNs also function as filters for lymph-born antigens ([@bib63], [@bib64]). Soluble antigens reach the LN first in a wave of draining-type diffusion ahead of a secondary wave of migratory antigen-presenting cells. Collected by lymphatic capillaries in the peripheral tissue, the lymph converges in afferent lymphatic vessels that merge with the LN capsule and flows within the subcapsular sinus (SCS). The lymph percolates through trabecular and cortical sinuses that flow into the LN medulla before leaving via efferent lymphatic vessels. A sample of low-molecular-weight molecules (\<70 kDa) ([@bib27], [@bib52], [@bib71], [@bib78]) is permitted to flow directly through the LN parenchyma within an intricate tubular system called the conduit network ([@bib71]). The conduit network is composed of bundled and aligned extracellular matrix (ECM) components enwrapped by FRCs, the main producers of ECM in the LN ([@bib42], [@bib78], [@bib79]). No other fibrillar ECM structures are found in the LN parenchyma. While we are starting to understand how the FRC network reacts during LN expansion, it is not yet known how the non-cellular ECM components are remodeled and how rapid expansion of the LN may affect the function of the conduit. In other contexts, inflammation goes hand in hand with tissue remodeling. Injury-induced loss of the ECM is rapidly replenished by biogenesis and crosslinking ([@bib93]). Chronic inflammation, as it occurs in cancers or some viral infections, induces deregulation of this process, leading to fibrosis ([@bib92]). LN fibrosis can occur in tumor-draining LNs or in some cases of chronic viral infection ([@bib66], [@bib70], [@bib74], [@bib97]); however, more commonly, LNs undergo a virtually unlimited number of inflammatory episodes throughout an individual's lifetime and LN fibrosis does not occur. Therefore, we hypothesized that a specific mechanism must be in place to both confine ECM secretion exclusively to the conduit and to avoid the accumulation of aberrant ECM during inflammation.

In this study, we focus on ECM remodeling by FRCs during LN expansion and the interconnection between the cellular and ECM components of the conduit network. We demonstrate depletion and disruption of ECM components of the conduit during acute LN expansion. We show that CLEC-2 binding to PDPN^+^ FRCs modulates ECM production at both mRNA and protein levels. Furthermore, the CLEC-2/PDPN axis regulates polarized microtubule organization in FRCs to direct and contain ECM deposition.

Results {#sec2}
=======

Extracellular Matrix Components of the Conduit Are Reduced during Acute LN Expansion {#sec2.1}
------------------------------------------------------------------------------------

To ask how ECM structures were maintained and remodeled during acute LN expansion, a period of rapid tissue growth, we first examined LN ECM structures in the steady state. Using the passive clarity technique (PACT) ([@bib94]), we imaged collagen IV in intact naive inguinal LNs ([Figure 1](#fig1){ref-type="fig"}A; [Video S1](#mmc2){ref-type="supplementary-material"}). This abundant basement membrane protein surrounded the LN vasculature and formed an intricate 3D connected network spanning the whole LN parenchyma ([@bib42], [@bib78], [@bib79]), corresponding to the conduit network. Electron microscopy revealed the detail of condensed fibrillar bundles consisting of \>200 collated fibers of ECM enwrapped by FRCs ([Figure 1](#fig1){ref-type="fig"}B). Co-staining of the basement membrane protein laminin and the FRC marker PDPN confirmed that in LN parenchyma, ECM structures are found exclusively associated with the FRC network forming the conduit ([@bib5]) and vasculature ([Figure 1](#fig1){ref-type="fig"}C).Figure 1Conduit Composition Changes during LN Expansion(A) Representative maximum z stack projection of intact naive lymph node stained for collagen IV using PACT. Scale bar, 100 μm.(B) Representative transmission electron microscopy of naive LNs. Scale bars, 5 μm.(C) Representative cryosection of a naive LN. Tile scan (top) and magnification (bottom). Dashed line indicates T and B cell boundaries. Scale bars, 500 μm (tile scan).(D) Cryosections of the T cell area naive and inflamed LNs immunized with IFA/OVA. Scale bars, 100 μm.(E) Quantification of collagen IV in the PDPN^+^ network within the T cell area. Each point represents the median gray intensity of region of interest, from 5 biological replicates. Error bars represent means and SDs. ^∗∗∗^p \< 0.0005.(F) Quantification of collagen I within the PDPN^+^ network. Each point represents the median gray intensity of region of interest, from 3 biological replicates. Error bars represent means and SDs. ^∗∗^p \< 0.005.(G) Quantification of collagen VI within the PDPN^+^ network. Each point represents the median gray intensity of region of interest, from 5 biological replicates. Error bars represent means and SDs. ^∗∗∗∗^p \< 0.0001.

Video S1. Col4 PACT

We immunized mice with ovalbumin emulsified with incomplete Freund's adjuvant (IFA/OVA) and compared the density of collagen IV structures in LNs after 4 and 14 days ([Figure 1](#fig1){ref-type="fig"}D). We observed that the FRC network appeared stretched but connected at day 4 and that collagen IV structures were less prominent. Using podoplanin staining as a mask, we quantified collagen IV intensity exclusively within the FRC cellular network and found a progressive loss and disruption of conduit matrix over time in inflamed LNs ([Figure 1](#fig1){ref-type="fig"}E). We obtained similar results for collagen I and collagen VI ([Figures 1](#fig1){ref-type="fig"}F and 1G), indicating that while the FRC cellular network remained connected and intact, the accompanying ECM components of the conduit remained associated with the FRCs but were no longer replete.

CLEC-2 Binding Regulates ECM Production by FRCs {#sec2.2}
-----------------------------------------------

FRCs rapidly change their morphology and network architecture in response to CLEC-2^+^ migratory DCs ([@bib2]). We hypothesized that the remodeling of the cellular network may also affect the remodeling of the associated ECM downstream of the same DC/stromal contacts. We stimulated FRCs *in vitro* with CLEC-2-Fc recombinant protein and compared transcriptional profiles by RNA-seq ([Figures 2](#fig2){ref-type="fig"} and [S1](#mmc1){ref-type="supplementary-material"}). Bulk analysis of the transcriptomic data comparing 6- and 24-h CLEC-2-Fc treatment revealed that CLEC-2-Fc induced a transient and largely reversible gene regulation response in FRCs ([Figure S1](#mmc1){ref-type="supplementary-material"}A). This transient transcriptional regulation follows kinetics similar to how CLEC-2 inhibits PDPN-dependent contractility in FRCs ([@bib2]). Gene Ontology analysis ([@bib44], [@bib45]) showed that genes encoding proteins in the extracellular space/region were most enriched among CLEC-2-Fc-regulated genes ([Figure 2](#fig2){ref-type="fig"}A). Using the Matrisome database ([@bib47], [@bib48], [@bib49]) of all ECM proteins and associated factors, we found that FRCs expressed 570 of 743 matrisome genes *in vitro*, of which 75 (13%, across all matrisome categories) were regulated \>2-fold 6 h after CLEC-2-Fc binding ([Figures 2](#fig2){ref-type="fig"}B and [S1](#mmc1){ref-type="supplementary-material"}B).Figure 2Effects of CLEC-2 on ECM Production by FRCs(A) Gene Ontology analysis, genes regulated by CLEC-2-Fc ≥2-fold. RNA-seq data from 4 biological replicates per condition.(B) CLEC-2-Fc-regulated matrisomal gene cluster in a principal-component analysis (PCA) space. Arrows indicate time course.(C) Heatmaps of matrisomal genes regulated ≥2-fold by CLEC-2-Fc. Four biological replicates for each condition are shown. Color-coding represents *Z* score; row average is indicated (right).(D) Fibronectin (top) and collagen VI (bottom) representative immunofluorescence staining of *in vitro* FRC-derived matrices. Maximum z stack projections; scale bars, 20 μm.(E) Median gray intensity for ECM components. Each dot represents a region of interest, combined from 3 biological replicates. Error bars represent means and SDs. ^∗^p \< 0.05, ^∗∗^p \< 0.005, ^∗∗∗^p \< 0.0005, one-way ANOVA, Tukey's multiple comparisons test.

FRCs regulated 35 core matrisome genes (\>2-fold) in response to CLEC-2-Fc, including 1 collagen (*Col8a2*), 23 glycoproteins, and 6 proteoglycans ([Figure 2](#fig2){ref-type="fig"}C). The downregulated glycoproteins were mostly associated with cell-matrix adhesion and migration, including *Nov*, *Sparcl1*, *Ntn1*, *Igfbp5*, *Ndnf*, *Spon2*, *Efemp1*, and *Fbln7* ([@bib15], [@bib18], [@bib26], [@bib32], [@bib57], [@bib81], [@bib83], [@bib95]). The glycoprotein genes induced had more pleiotropic roles, such as growth factor signaling (*Ctgf*, *Tsku*, *Wisp1*, and *Ltbp2*) ([@bib19], [@bib40], [@bib51], [@bib58]) or immunomodulation (*Spp1*, *Tnc*, and *Crispld2*) ([@bib12], [@bib46], [@bib90]). The regulation of proteoglycan expression by CLEC-2-Fc was more evident at 24 h, suggesting that CLEC-2-Fc may be indirectly regulated (e.g., CTGF/CCN2 represses *Ogn*, *Dcn*, *and Omd*; [@bib75]). CLEC-2-Fc increased the expression of *Prg4*, which inhibits synoviocyte cell/matrix adhesion ([@bib62]).

Most of the 17 ECM-affiliated genes that were regulated by CLEC-2-Fc were linked to cytoskeleton regulation ([@bib3], [@bib11], [@bib28]) ([Figure 2](#fig2){ref-type="fig"}C), including members of the semaphorin-plexin system, which provides guidance cues for migration ([@bib11]). Known to inhibit axonal growth ([@bib11]), the expression of *Sema6c*, *Sema5a*, *Sema3f*, *Sema3e*, *Sema3a*, and *Sema3d* were reduced upon CLEC-2-Fc treatment, hinting that FRCs may spread using similar mechanisms. Of note, CLEC-2-Fc induced the expression of *Sema7a*, which represses ECM production in other fibroblasts ([@bib20]).

CLEC-2-Fc regulation of 23 ECM regulators ([Figure 2](#fig2){ref-type="fig"}C) mainly affected protease inhibitors, including the upregulation of *Serpine1*, *Timp1*, and *Timp3,* key in the negative regulation of matrix metalloproteinase (MMP) activity ([@bib23], [@bib98]). Also upregulated are *Sulf1* and *Tll1*, which are involved in ECM biogenesis ([@bib35], [@bib50]). CLEC-2-Fc repressed the expression of several ECM regulator genes with prominent roles in ECM degradation: *Hyal1* (hyaluronidase-1) ([@bib29]), *Agt* (SERPINA8/angiotensinogen) ([@bib69]), *Htra3* ([@bib8], [@bib88]), *Adamts1* ([@bib61]), *Adamts5* ([@bib21]), *Adamts7* ([@bib67]), *Adamts9* ([@bib96]), *Adamts15* ([@bib14]), *Adam9* ([@bib73]), and *Mmp16* ([@bib72]).

These data indicate that FRCs can substantially alter their transcriptional profile following CLEC-2 binding and that transcriptional regulation may play an important role in ECM remodeling and cell matrix adhesion in FRCs. Furthermore, the induction of protease inhibitors plus the repression of proteases suggest that the observed loss of ECM within the conduit during LN expansion ([Figure 1](#fig1){ref-type="fig"}D) is unlikely to be due to degradation by FRCs. Furthermore, since we observed that collagens (I, IV, and VI) are reduced *in vivo* in inflamed LNs ([Figure 1](#fig1){ref-type="fig"}D) but were not transcriptionally regulated by CLEC-2, this transcriptional regulation alone cannot fully explain the reduced ECM observed ([Figure 1](#fig1){ref-type="fig"}D).

To investigate whether the CLEC-2/PDPN signaling axis regulates ECM production at the protein level, we undertook a proteomic analysis of FRC-derived matrices *in vitro* ([Figure S2](#mmc1){ref-type="supplementary-material"}). We generated CLEC-2-Fc-secreting FRCs to allow constant CLEC-2 stimulation and compared them to PDPN-depleted FRCs (PDPN knockdown \[KD\]) ([@bib2]) and a control FRC cell line. Mass spectrometry analysis detected a similar number of proteins in all 3 FRC cell lines, in which 96 proteins were matrisomal proteins, with almost 90% overlap among the samples ([Figure S2](#mmc1){ref-type="supplementary-material"}A). PDPN depletion phenocopies the loss of contractility induced by CLEC-2 binding ([@bib2]); in contrast, when comparing ECM protein production, PDPN KD FRCs appeared qualitatively different from either control or CLEC-2-Fc-secreting FRCs ([Figure S2](#mmc1){ref-type="supplementary-material"}B). PDPN KD FRC-derived matrices showed an overall reduction in ECM components, whereas CLEC-2-Fc-secreting FRCs and controls were more closely aligned ([Figure S2](#mmc1){ref-type="supplementary-material"}C). This suggests that the loss of PDPN expression is not equivalent to CLEC-2 modulation of PDPN function in the case of matrix production.

While the CLEC-2/PDPN signaling axis influenced both matrix transcription ([Figures 2](#fig2){ref-type="fig"}A--2C) and protein production ([Figure S2](#mmc1){ref-type="supplementary-material"}), how these changes translated to fibril formation, relevant to conduit remodeling *in vivo*, was still unclear. Staining of decellularized FRC-derived matrices for fibronectin and collagen VI showed that ECM structures formed by CLEC-2-Fc-secreting FRCs appeared disorganized compared to controls, with lower alignment, large empty spaces, and lower median intensity of matrix fibers ([Figures 2](#fig2){ref-type="fig"}D and 2E). In this functional assay, PDPN KD FRCs phenocopied the effect of CLEC-2-Fc in matrix deposition and organization. These experiments demonstrate that CLEC-2/PDPN signaling regulates ECM remodeling at multiple levels, gene expression, protein production, and secretion and fibril arrangement. These results also indicate that PDPN expression by FRCs is a key requirement for FRCs to produce, deposit, and align ECM components, and that this process is modulated by CLEC-2.

Signaling Cascades Regulated by CLEC-2 in FRCs {#sec2.3}
----------------------------------------------

The above results suggest that additional cellular mechanisms are likely to regulate ECM deposition in FRCs. To address the CLEC-2/PDPN-dependent signaling cascades controlling ECM organization, we performed an unbiased phosphoproteomics analysis of FRCs by tandem mass tag mass spectrometry (TMT-MS) ([@bib85]) ([Figure 3](#fig3){ref-type="fig"}A). Control FRCs were stimulated with CLEC-2-Fc for 15 min or 24 h to capture immediate and late signaling responses. As expected, the total protein levels did not differ significantly following treatment ([Figure 3](#fig3){ref-type="fig"}B). However, phosphoproteome analysis revealed that CLEC-2-Fc induced a rapid and transient signaling response in FRCs ([Figure 3](#fig3){ref-type="fig"}C). At 15 min, ≈400 phosphorylation sites were regulated by CLEC-2-Fc ([Figure 3](#fig3){ref-type="fig"}D), corresponding to 77 proteins. In contrast, after 24 h, only 8 phosphorylation sites corresponding to 6 proteins were regulated compared to controls, confirming the transient and reversible nature of responses to CLEC-2/PDPN engagement ([Figure 3](#fig3){ref-type="fig"}D).Figure 3Phosphoproteomics of CLEC-2-Fc-Treated FRCs(A) Experimental setup, comparison of 5 control (untreated) and 5 CLEC-2-Fc-treated FRC cell lysates (biological replicates).(B) Waterfall plots showing proteome regulation by CLEC-2-Fc.(C) Control and CLEC-2-Fc-treated phosphoproteomes cluster in a PCA space.(D) Volcano plots showing statistical regulation of the CLEC-2-Fc-treated FRC's phosphoproteome (n = 5, two-tailed t test, Gaussian regression). The number of regulated phosphosites is indicated.(E) Empirical parent kinase analysis. The bars represent the number of targets for kinases. Positive and negative values indicate higher or lower phosphorylation in CLEC-2-Fc-treated cells.(F) Gene Ontology analysis for biological processes. Each bar represents a biological process significantly enriched by binomial analysis.

To elucidate signaling cascades regulated by CLEC-2, we performed kinase target analysis (15 min dataset). We found that CSNK2B and CDK1 regulated the highest number of predicted targets ([Figure 3](#fig3){ref-type="fig"}E). Gene Ontology analysis of hits ([@bib44], [@bib45]) highlighted intracellular protein transport pathways ([Figure 3](#fig3){ref-type="fig"}F) that were relevant to the transport and deposition of cargo such as ECM components. However, using a GFP-based assay, we found no reduction in protein secretion in either CLEC-2-Fc-treated or PDPN KD FRCs ([Figure S3](#mmc1){ref-type="supplementary-material"}). Nevertheless, the impaired ECM deposition that was observed in both CLEC-2-Fc-treated and PDPN KD FRCs ([Figure 2](#fig2){ref-type="fig"}D) prompted a closer look at the phosphoproteomic data. Secretion of large cargo proteins such as ECM components requires vesicle transport via such cytoskeletal structures as the microtubule network ([@bib53]). We found that several key regulators of microtubule function were post-translationally modified by CLEC-2-Fc stimulation, including cytoplasmic linker protein 170 (CLIP-170), cytoplasmic dynein heavy chain 1, and pleckstrin homology-like domain family B member 2 (LL5β). While the direct function of these regulatory sites has not been previously described, these data presented strong evidence that CLEC-2 altered the organization of microtubules in FRCs, a possible regulatory mechanism of ECM deposition in LNs.

CLEC-2 Binding Controls Microtubule Organization in FRCs via LL5β {#sec2.4}
-----------------------------------------------------------------

LL5β forms complexes that attach plus ends of microtubules to the cell membrane, providing a secretory pathway for localized exocytosis, which facilitates apicobasal cell polarity in epithelial cells ([@bib31], [@bib38], [@bib53], [@bib82]). Given that ECM components in LNs are tightly compartmentalized by FRCs within the conduit, we reasoned that FRCs may be using a similar pathway to secrete ECM. We therefore examined the role of LL5β in ECM deposition by FRCs. We found that both CLEC-2-Fc treatment and PDPN KD reduced LL5β protein and mRNA levels in FRCs ([Figures 4](#fig4){ref-type="fig"}A and 4B). We attempted unsuccessfully to overexpress a phosphomimetic mutant (LL5β S465E) in FRCs, leading us to hypothesize that phosphorylation of LL5β at S465 may target LL5β for degradation.Figure 4Regulation of Microtubule Organization by CLEC-2 via LL5β(A) Representative western blots showing LL5β expression in FRC cell lines.(B) Expression of LL5β mRNA relative to control FRCs by qPCR. Error bars represent means and SDs of 2 biological replicates.(C) Immunofluorescence of FRC cell lines *in vitro*. Maximum z stack projections. Scale bars, 10 μm.(D) Quantification of LL5β coverage in FRC cell lines as a percentage of the total perimeter. Each dot represents 1 cell. Error bars represent means and SDs. ^∗∗∗∗^p \< 0.00005, one-way ANOVA, Tukey's multiple comparisons test.(E) α-Tubulin intensity in the cortical area (10 μm from the edge) of FRC cell lines. Each dot represents 1 cell. Error bars represent means and SDs. ^∗∗∗∗^p \< 0.00005, one-way ANOVA, Tukey's multiple comparisons test. NS, not significant.(F) α-Tubulin intensity in the cortical area (10 μm from the edge) in LL5β^+^ and negative areas in control FRCs relative to the total area. Black dots represent cells and blue dots represent cell areas. Error bars represent means and SDs. ^∗^p \< 0.05, one-way ANOVA, Tukey's multiple comparisons test.(G) Expression of LL5β mRNA by qPCR in LL5β siRNA transfected FRCs (n = 2). Error bars represent means and SDs.(H) αTubulin intensity in the cortical area (10 μm from the edge). Each dot represents 1 cell. Error bars represent means and SDs. ^∗∗^p \< 0.005, ^∗∗∗^p \< 0.0005, one-way ANOVA, Tukey's multiple comparisons test.(I) Representative *in vitro* cell-derived matrices from LL5β KD FRCs, decellularized and stained for fibronectin. Maximum z stack projections. Scale bars, 100 μm.(J) Median gray intensity for fibronectin staining. Each dot represents a different region of interest, from 2 biological replicates. Error bars represent means and SDs.

Control FRCs clustered LL5β at the cell periphery ([Figure 4](#fig4){ref-type="fig"}C); however, this accumulation was absent in PDPN KD FRCs and more cytoplasmic in CLEC-2-Fc-treated cells ([Figures 4](#fig4){ref-type="fig"}C and 4D). The reduced peripheral localization of LL5β coincided with the lower density of microtubules at the cell periphery in PDPN KD and CLEC-2-Fc-treated cells ([Figure 4](#fig4){ref-type="fig"}E). We confirmed the colocalization of LL5β with cortical microtubules in control FRCs, in which LL5β^+^ areas presented a higher microtubule density compared to areas lacking LL5β ([Figure 4](#fig4){ref-type="fig"}F). To investigate whether LL5β was required for microtubule attachment to the cortex in FRCs, we silenced LL5β expression using small interfering RNA (siRNA) ([Figure 4](#fig4){ref-type="fig"}G), which resulted in a corresponding loss of microtubules from the periphery ([Figure 4](#fig4){ref-type="fig"}H). LL5β-silenced FRCs also showed significantly reduced matrix deposition ([Figures 4](#fig4){ref-type="fig"}I and 4J), phenocopying the disrupted matrix generated following either CLEC-2-Fc treatment or PDPN depletion ([Figure 2](#fig2){ref-type="fig"}H) and confirming that LL5β is necessary for ECM deposition in FRCs.

Loss of FRC Adhesion and Reorganization of Microtubule Networks {#sec2.5}
---------------------------------------------------------------

LL5β is recruited to mature focal adhesion complexes, which require Rho-kinase (ROCK)/myosin-mediated contractility ([@bib34], [@bib82]). Since the CLEC-2/PDPN signaling axis inhibits actomyosin contractility in FRCs ([@bib2]), we predicted it may also alter FRC adhesion to the underlying conduit and therefore inhibit the localization of LL5β and microtubules to the cell cortex. We compared the structure and localization of focal adhesions (p-paxillin) and LL5β between FRC cell lines. In controls, LL5β clustered directly adjacent to elongated mature focal adhesions ([@bib82]) ([Figures 5](#fig5){ref-type="fig"}A and 5B). However, CLEC-2-Fc-treated and PDPN KD cells presented significantly shorter focal adhesions ([Figures 5](#fig5){ref-type="fig"}A and 5B). This was phenocopied by the direct inhibition of ROCK (Y-27632) ([Figures 5](#fig5){ref-type="fig"}A and 5B). This result shows that when focal adhesion maturation is disrupted, there is a concordant loss of LL5β clustering, linking actomyosin contractility, cell matrix adhesion, and LL5β recruitment in an integrated mechanism ([Figures 5](#fig5){ref-type="fig"}A and 5B). To test these linked outcomes in a more physiological assay, we stimulated FRCs with either control or CD11c^ΔCLEC-2^ bone marrow-derived dendritic cells (BMDCs). Cultured alone, FRCs displayed prominent F-actin stress fibers and mature elongated focal adhesions to which microtubule bundles docked in abundance ([Figures 5](#fig5){ref-type="fig"}C and 5D). Interaction with control (CLEC-2^+^) BMDCs induced the loss of actin stress fibers, shorter focal adhesions, and lower microtubule density at the periphery ([Figures 5](#fig5){ref-type="fig"}C and 5D). This change in FRC morphology and function was not observed with CD11c^ΔCLEC-2^ BMDCs ([Figures 5](#fig5){ref-type="fig"}C and 5D), demonstrating that DC-induced inhibition of actomyosin contractility and microtubule localization requires CLEC-2.Figure 5Focal Adhesion, Microtubule Organization, and Contractility in FRCs(A and B) Representative immunofluorescence of FCR cell lines untreated and control FRCs treated with Y-27632 ROCK inhibitor. (A) Maximum z stack projections of representative images are shown. Scale bars, 5 μm. (B) Quantification of FA length from p-paxillin staining and LL5β coverage as a percentage of the total perimeter. Dots represent FAs (top) or single cells (bottom) from 2 biological replicates. ^∗∗^p \< 0.005, ^∗∗∗∗^p \< 0.00005, one-way ANOVA, Tukey's multiple comparisons test. Error bars represent SDs.(C) Immunofluorescence of FRC/DC cocultures control or CD11c^ΔCLEC-2^ BMDCs. Maximum z stack projections. Scale bars, 20 μm.(D) Quantification of FA length and α-tubulin intensity in the cortical area (10 μm from the edge). Dots represent FAs (top) or single cells (bottom) from 3 biological replicates. ^∗^p \< 0.05, ^∗∗^p \< 0.005, ^∗∗∗∗^p \< 0.00005, one-way ANOVA, Tukey's multiple comparisons test. NS, not significant. Error bars represent SDs.(E) Representative immunofluorescence of cryosections of naive and inflamed LNs immunized with IFA/OVA. Maximum z stack projections. Scale bars, 20 μm. Asterisks and arrowheads indicate conduit-associated and conduit-independent surfaces, respectively, of FRCs.(F) Quantification of the indicated conduit components within the PDPN network. Each dot represents the median gray intensity of a different region of interest from 5 biological replicates. Error bars represent means and SDs. ^∗^p \< 0.05, ^∗∗∗∗^p \< 0.00005, unpaired t test.

We next asked whether LL5β directs the microtubule-mediated deposition of matrix components in the FRC network *in vivo*. High-resolution imaging of LN tissue revealed that in naive LNs, the entire FRC network expressed high levels of LL5β, and its localization was always polarized inward toward the ensheathed conduit ([Figure 5](#fig5){ref-type="fig"}E). In contrast, in inflamed LNs, we observed many regions of the FRC network that lacked polarized localization of LL5β, coinciding with the loss of laminin in the same region ([Figure 5](#fig5){ref-type="fig"}E). This is a direct translation of the *in vitro* studies that predicted the loss of LL5β when matrix adhesion is lost ([Figures 4](#fig4){ref-type="fig"} and [5](#fig5){ref-type="fig"}). These data require us to consider FRCs as polarized cells, exhibiting apical and basolateral cell polarity similar to epithelial sheets ([@bib53]), but enwrapping the conduit similar to Schwann cells enwrapping nerve fibers ([@bib89]). The inner surface of the FRC adheres to the conduit and recruits LL5β for ECM secretion, while the outer surface of the FRC excludes ECM, allowing optimal interaction with lymphocytes and antigen-presenting cells. Polarized and localized exocytosis in FRCs, directed by LL5β, can mechanistically explain how ECM components are exclusively found within the conduit and not elsewhere in the LN parenchyma.

Conduit Size Exclusion and Flow Persist during LN Expansion {#sec2.6}
-----------------------------------------------------------

We next asked how remodeling the ECM would affect conduit function. We compared the flow of fluorescently labeled dextrans through the LN sinuses and conduits of naive and acutely inflamed LNs (5 days post-immunization). It has been previously shown that 10-kDa dextrans can flow through the conduit, while those \>70 kDa are too large and are retained in the subcapsular sinus ([@bib27], [@bib52], [@bib71], [@bib78]). In accordance with previous studies, the 500 kDa dextran was excluded from all but the most proximal branches of the conduit in both naive and inflamed LNs ([Figure S4](#mmc1){ref-type="supplementary-material"}A), meaning that the filtering function and size exclusion of the conduit network are maintained during LN expansion ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Furthermore, these results indicated that ECM loss within the network did not impede the overall flow of small soluble molecules through LNs.

However, looking in more detail, we noticed the presence of numerous gaps or interruptions in dextran flow (10 kDa) through inflamed LNs, in which only \<20% of the FRCs network was dextran^+^ in inflamed LNs ([Figure 6](#fig6){ref-type="fig"}A, right panel). We found that the presence of dextran flow in inflamed LNs perfectly correlated with FRCs that had maintained both polarized LL5β and laminin ([Figure 6](#fig6){ref-type="fig"}B), indicating that conduit function is dysfunctional in many sections of the FRC network. However, despite the substantial reduction in conduit structures during acute expansion, the overall global distribution of small molecules through the conduit is maintained, reinforcing the robustness of the FRC network ([@bib54]).Figure 6Conduit Flow and Antigen Uptake in Inflamed LNsMice were immunized by the subcutaneous injection of IFA/OVA on the right flank. Five days later, fluorescently labeled 10 kDa dextran was injected on both flanks.(A) Immunofluorescence of 20-μm-thick cryosections of naive and inflamed draining LNs 30 min post-dextran injection. Maximum z stack projections. Scale bars, 40 μm. Graph shows the percentage of dextran^+^ areas within the PDPN^+^ network. Each dot represents a different region of interest. Regions of interest are collated from 6 individual mice per group. Error bars represent means and SDs. ^∗∗∗∗^p \< 0.0001, unpaired t test.(B) Immunofluorescence of 20-μm-thick cryosections of naive and inflamed draining LNs 30 min post-dextran injection. Maximum z stack projections. Scale bars, 20 μm. The asterisk indicates a portion of the FRC network with all conduit components plus dextran flow. The arrowhead indicates a portion of the FRC network in which the conduit is not present and dextrans are not flowing.(C) Percentage of dextran^+^ cells as quantified by flow cytometry 90 min after dextran injection. Error bars represent means and SDs.(D) The number of dextran^+^ cells per LN (i); the number of MHCII^+^ dextran^+^ cells (ii); the number of dextran^+^ cells within myeloid subsets (iii). Each dot represents an individual mouse (n = 6). Error bars represent means and SDs.(E) Representative images of CD11b^+^ myeloid cells in cryosections of the fibroblastic reticular network. Scale bars, 20 μm.(F) Quantification of the percentage (left) and the number (right) of CD11b^+^ myeloid cells interacting with conduit structures from regions of interest from 5 biological replicates. Error bars represent means and SDs.

Conduit Sampling by CD11b^+^ Cells Is Increased in Inflamed LNs {#sec2.7}
---------------------------------------------------------------

Soluble antigen flow through the conduit ensures controlled antigen sensing by LN resident cells ([@bib27], [@bib52], [@bib59], [@bib71], [@bib78]). We asked whether the interruptions in conduit flow observed in inflamed LNs would affect antigen uptake. Using flow cytometry, we found a similar percentage of dextran^+^ cells in inflamed LNs compared to naive ([Figure 6](#fig6){ref-type="fig"}C) within 90 min post-dextran injection. The total number of dextran^+^ cells was approximately doubled, but this is in line with the increase in LN cellularity ([Figure 6](#fig6){ref-type="fig"}Di). We found increased numbers of dextran^+^ cells within both MHC-II^−^ and MHC-II^+^ populations ([Figure 6](#fig6){ref-type="fig"}Dii), with MHC-II^+^ cells representing 80% of all dextran^+^ cells ([Figure S5](#mmc1){ref-type="supplementary-material"}B), the majority of these being CD11c^−/low^CD11b^+^ (monocytes/macrophages) cells in inflamed LNs ([Figure 6](#fig6){ref-type="fig"}Diii). Upon examination of the tissue sections, we found that the increased numbers of dextran^+^ monocytes/macrophages in inflamed LNs may result from the active recruitment of more CD11b^+^ monocytes/macrophages to conduits ([Figure 6](#fig6){ref-type="fig"}E). We observed double the number of CD11b^+^ cells interacting with the FRC network per area compared to naive controls ([Figures 6](#fig6){ref-type="fig"}E and 6F). Overall, we find that despite the local loss of conduit function ([Figure 6](#fig6){ref-type="fig"}A), the global robustness of the conduit network together with the increased monocytes/macrophage recruitment to conduits is able to maintain soluble antigen uptake throughout LN expansion.

Discussion {#sec3}
==========

Our results show that conduit flow within the T cell area conduit network is locally compromised during adaptive immune responses and that ECM components are lost or effectively diluted during early LN expansion. As a result, we observe discontinuous conduit flow within inflamed LNs, indicating areas of potential leakage. However, if conduits were leaking soluble antigens, then we may expect increased indiscriminate uptake by the many phagocytic cells within the tissue. Instead, we see that dextrans continue to be sampled from the conduits by a subset of myeloid cells and that an increased number of CD11b^+^ monocytes/macrophages are recruited to interact with the FRC network. We conclude that the conduit network is sufficiently robust in offering alternative routes around the dysfunctional sections. Conduit size exclusion requires plasmalemma vesicle-associated protein (PLVAP) expression by the lymphatic endothelial cells lining the sinus ([@bib65]). Our study provides further evidence that this barrier remains intact during early LN expansion, continuing to protect lymphoid tissue from intact pathogens.

Previous work has described the complex architecture of the conduit network in the steady state, and it is known that FRCs produce and organize ECM components ([@bib42], [@bib71], [@bib78], [@bib79]). We show that FRCs exhibit a type of apical/basolateral cell polarity and organize microtubule networks to direct ECM deposition unilaterally into conduit structures. Recruitment of LL5β facilitates the docking and attachment of the plus ends of microtubules to the cell membrane at sites of FRC-matrix adhesion and enables matrix deposition.

We found that CLEC-2 binding to FRCs regulates their matrix remodeling at both transcriptional and protein levels and also regulates FRC adhesion, contractility, and microtuble networks via LL5β recruitment, transiently inhibiting matrix deposition. This mechanism would explain how LNs are able to avoid the aberrant accumulation of excess ECM while enduring repeated episodes of inflammation. We have previously shown that CLEC-2^+^ DCs inhibit PDPN-dependent contractility in FRCs ([@bib2]). This weakens FRC adhesion and in turn inhibits the recruitment of LL5β to the conduit. LL5β expression is essential for FRCs to organize microtubules and form ECM matrices, and it is exclusively localized basolaterally in FRCs in association with laminin *in vivo*. We find that LL5β basolateral localization is disrupted during LN expansion, which can account for the progressive loss of ECM during LN expansion.

Our results confirm that the FRC cellular network remains connected in inflamed LNs ([@bib2], [@bib4]), even though the conduit flow is locally disrupted. This also indicates that FRC-FRC connectivity is prioritized over maintaining ECM production. Our data suggest that to expand the LN rapidly, FRCs detach temporarily from the conduit and halt matrix production, leading to the local loss of conduit function as pre-existing ECM fibers are stretched through the expanding tissue. However, the remaining intact sections of conduit are sufficient to channel the lymph throughout the LN parenchyma. Recent observations based on FRC ablation and a graph theory-based systems biology approach have demonstrated that FRCs establish "small-world" networks ([@bib54], [@bib87]). High local connectivity ensures the high topological robustness of the FRC network, which can tolerate the loss of 50% of all FRCs ([@bib54]). We propose that a similar principle applies to conduit flow, in which interruption of the conduit network is efficiently overcome by sufficient alternative routes. These findings lead us to the question of how conduit flow is determined, whether as a result of pressure from tissues and afferent lymphatics pushing fluid through the conduit network or, alternatively, whether the draw of fluid leaving the system via high endothelial venules (HEVs) and efferent vessels provides a pulling force. Since we find no evidence for leakiness of conduits, which may be predicted in a model of pushing forces, our data may suggest that flow is determined by pull from the circulation. We cannot exclude that the dysfunctional conduit flow that we observe in many sections of the FRC network ([Figure 6](#fig6){ref-type="fig"}) is not due to a disruption or an alteration in the drainage of tissue fluid such that conduits do not fill properly.

In contexts outside the LN, PDPN is often upregulated by fibroblasts in inflammatory settings ([@bib30], [@bib36], [@bib77]). In these scenarios, the ECM deposition by these fibroblasts could also be regulated and modified by contact with CLEC-2^+^ myeloid cells or platelets leaking from inflamed vessels. It will be interesting to understand whether the same CLEC-2-dependent transcriptional and protein expression regulation occurs in other PDPN^+^ fibroblasts. Since the CLEC-2/PDPN signaling axis also regulates FRC actomyosin contractility, this signaling pathway may also control how ECM is aligned and organized in other tissues.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------
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Lead Contact and Materials Availability {#sec4.2}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Sophie E. Acton (<s.acton@ucl.ac.uk>).

Key resources including details of key reagents and cell lines used and generated are available in the [Key Resources Table](#sec4.1){ref-type="sec"}. All unique/stable reagents generated in this study are available from the Lead Contact with a completed Materials Transfer Agreement.

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Mice {#sec4.3.1}

Experiments were performed in accordance with national and institutional guidelines for animal care and approved by the Institutional Animal Ethics Committee Review Board, Cancer Research UK and the UK Home Office. Wild-type C57BL/6J mice were purchased from Charles River Laboratories. PDGFRaKI-H2BGFP mice (B6.129S4-Pdgfratm11(EGFP)Sor/J) were purchased from Jackson Laboratories. Generation of CD11c^ΔCLEC-2^ was achieved as previously described ([@bib2]) by crossing Clec1b^fl/fl^ with CD11c-Cre mice (B6.Cg-Tg(Itgax-cre)1.1Reiz). Both males and females were used for *in vivo* and *in vitro* experiments and were aged 8--12 weeks. Cre-negative littermates were used as controls in all experiments.

### Animal procedures {#sec4.3.2}

#### Immunisations {#sec4.3.2.1}

Mice were immunized via subcutaneous injection in the right flank of 100 μL of an emulsion of OVA in CFA or IFA (100 μg OVA per mouse) (Hooke Laboratories). After 5 days, mice were culled and inguinal LNs from both flanks (naive and inflamed) were extracted for paired histological studies or flow cytometry analysis.

#### Dextran uptake in vivo {#sec4.3.2.2}

Five days after immunization, mice were injected subcutaneously in both flanks with 20 μL of dextran solution (100 μg dextran per flank) conjugated to: Cascade Blue (10kDa dextran), Tetramethylrhodamine (70 kDa dextran) or Fluorescein (500 kDa dextran), all from Thermo Fisher Scientific. Mice were culled and paired inguinal LNs (inflamed versus non-inflamed) collected after 30 or 90 minutes for histological and flow cytometry analysis respectively.

#### Cell lines {#sec4.3.2.3}

*In vitro* experiments were performed using immortalized WT (control) and PDPN knockdown mouse FRC cell lines previously described ([@bib2]). For CLEC-2-Fc expression by FRCs, *Clec1b* cDNA was cloned into pFUSE-rIgG-Fc2 plasmids (Invivogen) and transfected into WT FRCs using lipofectamine 2000 (Thermo Fisher Scientific). Transfected cells were selected by prolonged culture with zeocin 100 μg/ml (Invivogen) and secretion of CLEC-2-Fc was confirmed by western blotting for cell-derived supernatants (data not shown).

FRC cell lines were cultured in DMEM plus glutamax (Life Technologies, Invitrogen) supplemented with 10% FBS, Penicillin-Streptomycin (100 U/mL) and 1% Insulin-Transferrin-Selenium (Life Technologies, Invitrogen) at 37°C in 10% CO~2~. Cells were passaged when they reached 80%--90% confluence, by incubating in Cell Dissociation Buffer (Thermo Fisher Scientific) for 10 minutes at 37°C, plus a gentle treatment of 1 min with Trypsin 0.25% (Thermo Fisher Scientific). When indicated, FRCs were treated with 50 μg/ml CLEC-2-Fc or 10 μM ROCK inhibitor Y-27632 dihydrochloride (Tocris) for the last 2 hr of culture.

#### Primary cultures {#sec4.3.2.4}

Bone marrow cells were obtained from tibias and femurs from CD11c^ΔCLEC-2^ mice and Cre-negative control littermates. Whole bone marrow was cultured in non-treated 10 cm Petri dishes in RPMI media supplemented with 10% FBS and Penicillin-Streptomycin (100 U/mL) plus 20 ng/ml of recombinant murine GM-CSF (Peprotech) at 4x10^6^ cells / 13 mL of medium. After 3 days, cultures were supplemented with 4 mL of fresh media plus 37.2 ng/ml GM-CSF. After 6 days in culture, BMDCs were stimulated with 10 ng/ml Lipopolysaccharides from *Escherichia coli* 0111:B4 (Sigma-Aldrich) for 24 hr before harvesting.

Method Details {#sec4.4}
--------------

### Tissue clearing and immunostaining of intact LNs {#sec4.4.1}

We used a modified version of the PACT (passive clarity technique) for whole LN staining based on previous publication ([@bib94]). In brief, AntigenFix (DiaPath) fixed LNs were incubated overnight at 4°C in 40% acrylamide + 25 mg/ml 2,2′-Azobis(2-methylpropionamidine) dihydrochloride (Sigma). Infused samples were degassed with nitrogen for 5 min and then incubated for 6 hr at 37°C. Samples were washed in PBS for 24 hr and incubated for 4 days with 8% SDS PBS solution at 37°C. After washing with PBS for 24 hr, LNs were incubated with 1:100 anti-collagen IV in PBS 2% goat serum (Abcam) 0.1% Triton X-100 (Sigma-Aldrich) 0.01% sodium azide (Webscientific) for 4 days at 37°C (rotation). Same concentration of the antibody was added after 1 and 2 days. Then wash in PBS at 37°C (rotation) for 24 hr and incubated with the secondary antibody in same conditions as the primary. Samples were transferred to a 2 g/ml Histodenz (Sigma-Aldricht), 0.01% sodium azide solution in PBS, incubated for 24 hr and imaged in this medium. Imaging was performed on a Leica TCS SP8 STED 3X using HC FLUOTAR L VISIR 25x water lenses.

### Electron microscopy of LN conduits {#sec4.4.2}

LNs were fixed overnight in 2% PFA/1.5% glutaraldehyde (both EM grade from TAAB) in 0.1M sodium Cacodylate at 4°C and embedded in 2.8% low melting point agarose dissolved in PBS. Slices of 100 μm thickness were then cut in cold PBS using a vibrating microtome (VT1200S; Leica) and returned to fresh fix solution for a further 15 mins. Slices were then secondarily fixed for 1 h in 1% osmium tetraoxide/1.5% potassium ferricyanide at 4°C and then treated with 1% tannic acid in 0.1M sodium cacodylate for 45min at room temperature. Samples were then dehydrated in sequentially increasing concentration of ethanol solutions, and embedded in Epon resin. The 70nm ultrathin resin sections were cut with a Diatome 45° diamond knife using an ultramicrotome (UC7; Leica). Sections were collected on 1 × 2mm formvar-coated slot grids and stained with Reynolds lead citrate. All samples were imaged using a transmission electron microscope (Tecnai T12; FEI) equipped with a charge-coupled device camera (SIS Morada; Olympus).

### Immunostaining of tissue sections {#sec4.4.3}

LN samples were fixed in AntigenFix (DiaPath) overnight, washed and incubated in PBS 30% sucrose (w/v) (Sigma-Aldrich) overnight at 4°C. Samples were embedded in Tissue-Tek® O.C.T. Compound (Thomas Scientific) and frozen using 2-Methylbutane, cooled with liquid nitrogen. 20 μm sections were cut using a Leica CM1850 cryostat. For immunostaining, tissue sections were blocked for 2 hr at room temperature in 10% goat normal Serum (Sigma-Aldrich), 0.3% Triton X-100 (Sigma-Aldrich) in PBS. Primary antibodies were incubated overnight at 4°C in 10% goat normal Serum (Sigma-Aldrich), 0.01% Triton X-100 (Sigma-Aldrich) in PBS. 3 washing steps were used to remove unbound antibody, before incubation with the secondary antibody plus Hoechst (Fisher Scientific) for 2 hr at room temperature. Samples were washed and mounted in mowiol. Samples were imaged on a Leica TCS SP8 STED 3X using HC PL APO CS2 /1.4 63x oil lenses.

### Image analysis {#sec4.4.4}

#### Conduit components {#sec4.4.4.1}

Podoplanin staining was used to define the FRC network in LN frozen tissue sections. Podoplanin signal was filtered by Gaussian Blur (sigma = 2) to remove background and thresholded identically in all samples. We next created a selection that was used in the corresponding channels in order to obtain the median intensity of the conduit components. We performed this process in a number of regions of interest within the T cell area for each LN, always minimizing the presence of vasculature.

#### Semiautomated quantification of focal adhesion length {#sec4.4.4.2}

Signal for phospho-Paxillin staining was thresholded equally in all samples after removal of background noise by Gaussian Blur (sigma = 2). Focal adhesions were segmented using the analyze particle tool in Fiji and fit ellipse. Major axis of the ellipse was used as an estimation of focal adhesion length.

### RNaseq analysis {#sec4.4.5}

FRCs were cultured for 24h, adding 50 μg/ml of CLEC-2-Fc from then beginning or 6 hours before collecting cells. Cells were left untreated as a control. RNA extractions were performed using the RNAeasy kit (QIAGEN) following the manufacturer's instructions, including a DNA digestion step to avoid genome contamination in further analysis.

For transcriptome sequencing and analysis, RNA preparations from FRCs were sequenced to a depth of 9 million to 22 million reads by Queen Mary University (QMUL) Genome Centre. The raw read quality control was performed by the QMUL Genome Centre using BaseSpace Illumina software. Paired end FASTQ files were then aligned to *Mus musculus* GRCm38 reference assembly using STAR aligner software ([@bib16]). Transcripts were assembled and relative transcript abundance were calculated using Salmon software ([@bib60]). Using R (v3.4.4) and the Bioconductor tximport package ([@bib80]), TPM (Transcripts per million) values were generated and annotated with ENSEMBL gene IDs. Bulk TPM data were categorised by the fold change (\> 2 fold) between control, 6 hr and 24 hr conditions using an in-house developed R script. Gene Ontology analysis were performed using the PANTHER software ([@bib45], [@bib44]) and PCA plots were generated using the ggplot package in R.

### FRC-derived matrices {#sec4.4.6}

FRC-derived matrices were generated *in vitro* according to published methods ([@bib24]). In brief, gelatin-coated wells were used to culture FRC cell lines at 5x10^3^ cells/cm^2^ in culture media supplemented with 50 μg/ml L(+)-Ascorbic acid sodium salt (Sigma-Aldrich) for 5 days, unless otherwise stated. Supplemented media was replenished at day 1 and 3. For proteomic analysis, cells in their matrix were collected in PBS, centrifuged and resuspended in 4M Urea. For microscopy analysis, cells were lysed incubating for 15 min at 37°C in PBS 1% Triton X-100 20 mM ammonium hydroxide. Matrices were blocked with 2% bovine serum albumin (w/v) (Sigma-Aldrich) and stained with the indicated antibodies. Samples were imaged with a Leica TCS SP5 Confocal Microscope using 63X oil HCX PL APO lenses.

### Proteomics of FRC-derived matrices {#sec4.4.7}

Quantitative proteomic analysis of the FRC-derived matrices was performed by sequential window acquisition of all theoretical spectra mass spectrometry (SWATH MS). For construction of the spectral library, FRCs and derived matrices were washed in PBS, centrifuged and enriched for extracellular matrix as previously described in Krasny et al. ([@bib37]). Enriched matrices were digested using gel-assisted protocol ([@bib76]) and desalted prior analysis by liquid chromatography-tandem mass spectrometry (LC-MS/MS) on Agilent 1260 HPLC coupled to TripleTOF 5600+ (SCIEX) mass spectrometer in data-dependent acquisition mode. For LC-MS/MS, peptides were spiked with iRT peptides (Biognosys AG), loaded on a 75 μm x 15 cm long analytical column packed with Reprosil Pur C18-AQ 3 μm resin (Dr Maisch) end eluted using a linear gradient of 2%--40% of Buffer B (98% ACN, 0.1% FA) in 90 min at flow rate of 250nl/min. Acquired datasets were searched by ProteinPilot 5.0.1 software (Sciex) against a Swissprot mouse database and spectral library was generated in Spectronaut 11 (Biognosys AG) from the results and combined with previously published library ([@bib37]). For quantitative analysis, FRCs and derived matrices were lysed on ice in 8M Urea, 100mM ammonium bicarbonate buffer and digested using gel-assisted protocol. Desalted peptides were spiked with iRT peptides and analyzed on the same LC-MS/MS instrument using identical LC conditions. MS/MS data were acquired in 60 SWATH windows with fixed size of 13 Da. SWATH spectra were analyzed in Spectronaut 11 with FDR restricted to 1%. Further statistical processing of median normalized data was performed in Perseus (1.5.6) ^91^.

### Isobaric Tandem Mass Tag (TMT) Phosphoproteomics {#sec4.4.8}

Isobaric Tandem Mass Tag (TMT) Phosphoproteomics were performed as described in [@bib85] (PMID: [27087446](pmid:27087446){#intref0025}). Following treatment, FRCs were lysed in 6 M urea, 10 mM NaPPi, 20 mM HEPES, pH 8.0, sonicated, centrifuged to clear cell debris, and protein concentration was determined by BCA (Pierce 23225). 200 μg of each condition were individually digested by FASP ([@bib91]), amine-TMT-10-plex-labeled (Pierce 90111) on membrane (iFASP) ([@bib43]), eluted, pooled, lyophilized, and subjected to automated phosphopeptide enrichment (APE) ([@bib84]). Phosphopeptides were desalted using OLIGO R3 resin (Life Technologies 1-1339-03) and lyophilized prior to liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis. Samples were run on a Q-Exactive Plus mass spectrometer (Thermo Scientific) coupled to a Dionex Ultimate 3000 RSLC nano system (Thermo Scientific). Reversed-phase chromatographic separation was performed on a C18 PepMap 300 Å trap cartridge (0.3 mm i.d. x 5 mm, 5 μm bead size; loaded in a bi-directional manner), a 75 μm i.d. x 50 cm column (5 μm bead size) using a 120 minute linear gradient of 0%--50% solvent B (MeCN 100% + 0.1% formic acid (FA)) against solvent A (H2O 100% + 0.1% FA) with a flow rate of 300 nL/min. The mass spectrometer was operated in the data-dependent mode to automatically switch between Orbitrap MS and MS/MS acquisition. Survey full scan MS spectra (from m/z 400-2000) were acquired in the Orbitrap with a resolution of 70,000 at m/z 400 and FT target value of 1x10^6^ ions. The 20 most abundant ions were selected for fragmentation using higher-energy collisional dissociation (HCD) and dynamically excluded for 30 s. Fragmented ions were scanned in the Orbitrap at a resolution of 35,000 (TMT) at m/z 400. The isolation window was reduced to 1.2 m/z and a MS/MS fixed first mass of 120 m/z was used to aid TMT detection. For accurate mass measurement, the lock mass option was enabled using the polydimethylcyclosiloxane ion (m/z 445.120025) as an internal calibrant. For peptide identification, raw data files produced in Xcalibur 2.1 (Thermo Scientific) were processed in Proteome Discoverer 1.4 (Thermo Scientific) and searched against SwissProt mouse (2011_03 release, 15,082,690 entries) database using Mascot (v2.2). Searches were performed with a precursor mass tolerance set to 10 ppm, fragment mass tolerance set to 0.05 Da and a maximum number of missed cleavages set to 2. Peptides were further filtered using a mascot significance threshold \< 0.05, a peptide ion Score \> 20 and a FDR \< 0.01 (evaluated by Percolator ([@bib33]). Phospho-site localization probabilities were calculated with phosphoRS 3.1 (\> 75%, maximum 4-PTM/peptide) ([@bib86]). Phosphopeptides from Proteome Discoverer 1.4 were normalized against total protein levels (from in-gel digest experiments), and protein-level phospho-site locations (phosphoRS 3.1 score \> 75%, maximum 4-PTM/peptide) were manually annotated using PhosphoSitePlus. Phosphoproteomic volcano plots display mean Proteome Discoverer 1.4 quantification fold-difference values across all replicates (log2) against two-tailed t test P values (calculated from arrays of raw MS/MS TMT intensity counts). Volcano plots were assembled in GraphPad Prism 6 (non-linear Gaussian regression, least-squares fit). For principle component analysis (PCA), Proteome Discoverer 1.4 quantification ratio values were converted to log2, imported into R (version 3.0.1), computed using the function 'princomp(X)' and plotted in GraphPad Prism. Empirical parent kinases were manually identified by referenced Uniprot annotation and putative parent kinases were manually assigned using ScanSite ([@bib56]) 3 ('High- Stringency' setting, top 0.2% of all sites, lowest score). Phospho-sites that did not meet these conditions were not annotated.

### GFP secretion assay {#sec4.4.9}

FRC cells lines were transfected with 500 ng of lumGFP plasmid ([@bib7]) using Attractene Transfection Reagent (QIAGEN) for 8 hr. Culture media was replenished with fresh media. After 15 hr, supernatants were collected and cells lysed in PBS 0.5% Triton X-100. Supernatants were centrifuged in order to remove cell debris. GFP levels in cell lysates and supernatants were measured by a solid-phase sandwich ELISA ([@bib6]). Briefly, polystyrene 96-well plates were coated overnight with 200 μl/well of PBS plus sheep anti-GFP 1:50,000 for 1 hr at room temperature. The antibody solution was removed and the plates were then incubated for 1 hr at room temperature to block nonspecific binding by using 300 μl/well of TEB (1% Triton X-100, 0.2% gelatin, 1 mM EDTA in PBS). The TEB was removed, each well was filled with 200 μL of samples or standard curve in TBE, and the plates were incubated while shaking for 1 hr. After extensive washing, plates were incubated with 200 μL TBE plus Rabbit anti-GFP 1:20,000 for 1 hr with shaking. Next, plates were washed and incubated with 200 μl/well of Goat anti-Rabbit HRP 1:3,000 in TBE for 1 hr plus shaking. Plates were washed three times in TBE and 3 times in PBS and using a standard o-phenylenediamine assay. Percentage of secreted GFP was calculated with respect to total GFP produced (supernatant plus lysates).

### Western Blotting {#sec4.4.10}

Equal number of cells were seeded and cultured for 24 hours. Cells were washed with cold PBS and lysed using Laemmli buffer (BioRad). All lysates were sonicated, heated for 10 min at 95°C and treated with 143 μM β-mercaptoethanol. Electrophoresis gels were loaded with the same quantity of lysates and run for 45 min at 130 V. Transfer to PDVF membranes were carried out at 65 V for 2 hr. Membranes were blocked for 2 hr at room temperature with 5% skim milk powder (Sigma-Aldrich), 2% BSA in PBS and stained with primary antibodies overnight at 4°C in 1:5 diluted blocking buffer. The next day, membranes were thoroughly washed in PBS 0.05% Tween 20 and incubated with HRP-conjugated secondary antibodies 1:5000 in 1:5 diluted blocking buffer.

### Quantitative RT-PCR analysis for Phldb2 (LL5β) messenger RNA {#sec4.4.11}

cDNA was generated from RNA samples using the SuperScript IV Reverse Transcriptase kit (Thermo Fisher Scientific), following manufacturer's instructions. Quantitative PCRs were run using the MESA Blue qPCR Mastermix (SYBR Assay). We used specific primers for detection of *Phldb2* mRNA transcripts 1 and 2 (PrimerBank ID 23510303a1): Forward Primer AGCCGCGTTTCTGAAAGCA (1653-1671); Reverse Primer CATCCGGGCGTCTTCCATT (1773-1755). Detection of GAPDH mRNA was used for normalization.

### Three-dimensional cell culture {#sec4.4.12}

FRCs were plated in 24-well MatTek plates at 3.5x10^3^ cell/cm^2^. Matured BMDCs were harvested and 150,000 cells were seeded per well in 150 μl collagen/matrigel matrix plus 20 ng/ml rmGM-CSF ([@bib1], [@bib10], [@bib25]). FRC:BMDC ratio 1:43. Gels were set at 37°C for 30 min. After 24 hr, cells were fixed, permeabilized and stained for the stated cellular components.

### Immunostaining of cells *in vitro* {#sec4.4.13}

Cells were plated on 13 mm coverslips. Cells were fixed for 15 min in 3.6% formaldehyde and permeabilized with Triton X-100 0.3% for 15 min, at room temperature. Cells were blocked with PBS 2% BSA for 1 hr at room temperature, followed by overnight incubation with corresponding primary antibodies in PBS 1% BSA. After washing, cells were incubated with Alexa Fluor-conjugated secondary antibodies plus Hoechst and/or phalloidin to reveal DNA in cell nuclei and F-actin respectively, all in PBS 1% BSA for 2 hr at room temperature, washed and mounted on glass slides for imaging. Samples were imaged in Leica TCS SP5 and SP8 STED 3X Confocal Microscopes using 63X HCX PL APO lenses or HC PL APO CS2 /1.4 63x oil lenses.

### LL5β silencing by siRNA {#sec4.4.14}

WT FRC cell lines were transfected with four different siRNAs targeting LL5β expression (Dharmacon, GE Healthcare) using lipofectamine 2000 (Thermo Fisher Scientific). After 24 hr transfection, cells were washed and cultured in fresh media for an additional 12 hours before silencing efficiency was determined by qPCR. The following two siRNAs were selected for further assays: \#1 GCAGAGUAUCAGCGGAACA and \#2 GAACAAUGAAGGACCGAGA. Scrambled RNA and non-template controls were used for comparison.

### Flow cytometry of LNs {#sec4.4.15}

Inguinal LNs were carefully dissected and digested using collagenase P at 200 μg/ml (Sigma-Aldrich), dispase II 800 μg/ml (thermos fisher scientific) and DNase I 100 μg/ml (Sigma-Aldrich) in RPMI at 37°C in a water bath. Every 10 min LNs were mixed by pipetting up and down and half of the digestion media replenished by fresh until all tissue was digested. Cell suspensions were centrifuged, resuspended in FACS buffer (PBS 2% FBS 10mM EDTA) and filtered through a 70 μm cell strainer (Corning). Cells were counted and approximately 1x10^6^ cells were used for immunofluorescence staining. In brief, cells were resuspended in 100 μL FACS buffer, treated with Fc blocking for 10 min on ice and incubated with the indicated antibodies for 30 min on ice. Cells were washed extensively and resuspended in 500 μL FACS buffer. Precision Count Beads (BioLegend) were used for accurate cell count. Samples were run in a Fortessa X20 flow cytometer (BD Biosciences) at the UCL Cancer Institute and analyzed using the FlowJo software (FlowJo, LLC). Live cells were gated by FSC/SSC parameters and doublets discriminated by comparing SSC-A versus SSC-H.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

Statistical parameters including the exact value of n, what n represents, precision measures (mean/median ± SD) and statistical significance are reported in the Figures and Figure Legends.

Statistical analysis was performed using Prism 7 (GraphPad Software). For *in vivo* experiments, naive versus inflamed LNs were compared by unpaired, parametric t test, assuming that both populations had the comparable standard deviation. For *in vitro* experiments and all other multiple comparisons, ordinary one-way ANOVA followed by Tukey's multiple comparisons test was performed.

Binomial test type for PANTHER Overrepresentation Test of cellular components (RNaseq) and biological process (Phosphoproteomics) was used to analyze changes induced by CLEC-2 binding to FRCs.

Data and Code Availability {#sec4.6}
--------------------------

RNaseq data and phospho-proteomics data are available: UCL research data repository: <https://doi.org/10.5522/04/c.4696979;> PRIDE repository ID = PXD015816
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